Shin Nippon Biomedical Laboratories, Ltd. (2395.T)
JPY 1537.0
(-1.22%)
JPY 1537.0
(-1.22%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 5.53 Billion JPY | -8.73% |
| 2022 | 6.06 Billion JPY | -14.98% |
| 2021 | 7.12 Billion JPY | 94.65% |
| 2020 | 3.66 Billion JPY | 43.58% |
| 2019 | 2.55 Billion JPY | 30.77% |
| 2018 | 1.95 Billion JPY | 154.85% |
| 2017 | -3.55 Billion JPY | -288.23% |
| 2016 | -915.93 Million JPY | -134.61% |
| 2015 | 2.64 Billion JPY | 290.96% |
| 2014 | -1.38 Billion JPY | -83.54% |
| 2013 | -754.99 Million JPY | 34.51% |
| 2012 | -1.15 Billion JPY | 65.11% |
| 2011 | -3.3 Billion JPY | -129.13% |
| 2010 | -1.44 Billion JPY | -369.77% |
| 2009 | 534.52 Million JPY | 360.05% |
| 2008 | -205.54 Million JPY | -134.27% |
| 2007 | 599.87 Million JPY | 10.32% |
| 2006 | 543.76 Million JPY | 103.35% |
| 2005 | 267.41 Million JPY | 156.6% |
| 2004 | -472.44 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 122.19 Million JPY | -92.96% |
| 2023 Q1 | 1.37 Billion JPY | -19.61% |
| 2023 Q2 | 1.59 Billion JPY | 15.99% |
| 2023 Q3 | 828.47 Million JPY | -47.99% |
| 2023 Q4 | 1.73 Billion JPY | 109.61% |
| 2023 FY | 5.53 Billion JPY | -8.73% |
| 2022 Q1 | 1.94 Billion JPY | 3.44% |
| 2022 Q3 | -68.07 Million JPY | -102.75% |
| 2022 Q4 | 1.7 Billion JPY | 2609.62% |
| 2022 FY | 6.06 Billion JPY | -14.98% |
| 2022 Q2 | 2.47 Billion JPY | 27.31% |
| 2021 Q2 | 1.67 Billion JPY | -8.18% |
| 2021 FY | 7.12 Billion JPY | 94.65% |
| 2021 Q1 | 1.82 Billion JPY | -16.41% |
| 2021 Q3 | 1.74 Billion JPY | 4.0% |
| 2021 Q4 | 1.87 Billion JPY | 7.76% |
| 2020 Q1 | 643.36 Million JPY | -31.92% |
| 2020 FY | 3.66 Billion JPY | 43.58% |
| 2020 Q4 | 2.18 Billion JPY | 547.58% |
| 2020 Q2 | 495.93 Million JPY | -22.92% |
| 2020 Q3 | 337.43 Million JPY | -31.96% |
| 2019 Q1 | -41.33 Million JPY | -110.74% |
| 2019 Q2 | 918.58 Million JPY | 2322.24% |
| 2019 Q3 | 728.19 Million JPY | -20.73% |
| 2019 FY | 2.55 Billion JPY | 30.77% |
| 2019 Q4 | 944.93 Million JPY | 29.77% |
| 2018 Q2 | 527.12 Million JPY | 36.88% |
| 2018 Q3 | 653.19 Million JPY | 23.92% |
| 2018 Q4 | 384.87 Million JPY | -41.08% |
| 2018 FY | 1.95 Billion JPY | 154.85% |
| 2018 Q1 | 385.1 Million JPY | 123.85% |
| 2017 Q4 | -1.61 Billion JPY | -454.57% |
| 2017 Q3 | -291.13 Million JPY | 72.16% |
| 2017 Q2 | -1.04 Billion JPY | -73.04% |
| 2017 FY | -3.55 Billion JPY | -288.23% |
| 2017 Q1 | -604.41 Million JPY | -169.59% |
| 2016 FY | -915.93 Million JPY | -134.61% |
| 2016 Q2 | -1.11 Billion JPY | 37.46% |
| 2016 Q3 | 1.1 Billion JPY | 199.59% |
| 2016 Q4 | 868.47 Million JPY | -21.66% |
| 2016 Q1 | -1.77 Billion JPY | -4619.75% |
| 2015 Q3 | 1.65 Billion JPY | 226.0% |
| 2015 Q2 | -1.31 Billion JPY | -156.13% |
| 2015 Q1 | 2.34 Billion JPY | 475.6% |
| 2015 FY | 2.64 Billion JPY | 290.96% |
| 2015 Q4 | -37.71 Million JPY | -102.28% |
| 2014 Q4 | -623.54 Million JPY | -20092.62% |
| 2014 FY | -1.38 Billion JPY | -83.54% |
| 2014 Q3 | -3.08 Million JPY | 98.18% |
| 2014 Q2 | -169.47 Million JPY | 71.26% |
| 2014 Q1 | -589.62 Million JPY | -270.95% |
| 2013 Q2 | -644.95 Million JPY | -139.57% |
| 2013 Q1 | -269.2 Million JPY | 21.86% |
| 2013 Q3 | -185.74 Million JPY | 71.2% |
| 2013 FY | -754.99 Million JPY | 34.51% |
| 2013 Q4 | 344.91 Million JPY | 285.69% |
| 2012 Q2 | -504.06 Million JPY | -33.42% |
| 2012 Q3 | 73.51 Million JPY | 114.58% |
| 2012 FY | -1.15 Billion JPY | 65.11% |
| 2012 Q1 | -377.79 Million JPY | 77.07% |
| 2012 Q4 | -344.53 Million JPY | -568.65% |
| 2011 FY | -3.3 Billion JPY | -129.13% |
| 2011 Q4 | -1.64 Billion JPY | -261.0% |
| 2011 Q3 | -456.44 Million JPY | 37.26% |
| 2011 Q2 | -727.52 Million JPY | -54.01% |
| 2011 Q1 | -472.38 Million JPY | -94.17% |
| 2010 Q4 | -243.29 Million JPY | 30.3% |
| 2010 Q3 | -349.07 Million JPY | 19.57% |
| 2010 Q1 | -415.66 Million JPY | -609.95% |
| 2010 FY | -1.44 Billion JPY | -369.77% |
| 2010 Q2 | -433.99 Million JPY | -4.41% |
| 2009 Q3 | 14.58 Million JPY | -92.01% |
| 2009 Q4 | -58.54 Million JPY | -501.34% |
| 2009 FY | 534.52 Million JPY | 360.05% |
| 2009 Q1 | 395.83 Million JPY | 103.59% |
| 2009 Q2 | 182.65 Million JPY | -53.86% |
| 2008 Q3 | -564.48 Million JPY | -127.87% |
| 2008 FY | -205.54 Million JPY | -134.27% |
| 2008 Q4 | 194.43 Million JPY | 134.44% |
| 2008 Q2 | -247.72 Million JPY | 0.0% |
| 2007 FY | 599.87 Million JPY | 10.32% |
| 2006 FY | 543.76 Million JPY | 103.35% |
| 2005 FY | 267.41 Million JPY | 156.6% |
| 2004 FY | -472.44 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| DNA Chip Research Inc. | -248.29 Million JPY | 2327.715% |
| Cosmo Bio Company,Limited | 442 Million JPY | -1151.417% |
| H.U. Group Holdings, Inc. | -7.55 Billion JPY | 173.233% |
| FALCO HOLDINGS Co., Ltd. | 1.66 Billion JPY | -232.008% |
| BML, Inc. | 6.03 Billion JPY | 8.332% |
| Human Metabolome Technologies, Inc. | 243.24 Million JPY | -2173.918% |
| Precision System Science Co., Ltd. | -1.12 Billion JPY | 593.211% |